Should I buy or sell Maravai LifeSciences stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Maravai LifeSciences in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MRVI shares. View MRVI analyst ratings or view top-rated stocks .

What is Maravai LifeSciences' stock price target for 2024?

8 Wall Street analysts have issued twelve-month price objectives for Maravai LifeSciences' stock. Their MRVI share price targets range from $7.00 to $24.00. On average, they predict the company's share price to reach $13.90 in the next twelve months. This suggests a possible upside of 158.8% from the stock's current price. View analysts price targets for MRVI or view top-rated stocks among Wall Street analysts .

How have MRVI shares performed in 2023?

Maravai LifeSciences' stock was trading at $14.31 at the beginning of the year. Since then, MRVI shares have decreased by 62.5% and is now trading at $5.37. View the best growth stocks for 2023 here .

When is Maravai LifeSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024. View our MRVI earnings forecast .

How were Maravai LifeSciences' earnings last quarter?

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) issued its earnings results on Tuesday, November, 7th. The company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.03) by $0.01. The firm had revenue of $66.87 million for the quarter, compared to analyst estimates of $75.23 million. Maravai LifeSciences had a trailing twelve-month return on equity of 9.38% and a net margin of 5.86%.

What ETFs hold Maravai LifeSciences' stock?

ETFs with the largest weight of Maravai LifeSciences (NASDAQ:MRVI) stock in their portfolio include Morningstar US Small Growth (MSGR) , Janus Henderson Small Cap Growth Alpha ETF (JSML) , First Trust Health Care AlphaDEX Fund (FXH) and Putnam BioRevolution ETF (SYNB) . WisdomTree U.S. SmallCap Fund (EES) .

What guidance has Maravai LifeSciences issued on next quarter's earnings?

Maravai LifeSciences updated its FY23 earnings guidance on Tuesday, November, 7th. The company provided earnings per share (EPS) guidance of ($0.01) - $0.01 for the period, compared to the consensus EPS estimate of $0.06. The company issued revenue guidance of $275-285 million, compared to the consensus revenue estimate of $308.70 million.

When did Maravai LifeSciences IPO?

(MRVI) raised $1.3 billion in an IPO on Friday, November 20th 2020. The company issued 50,000,000 shares at a price of $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs acted as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers.

Who are Maravai LifeSciences' major shareholders?

Maravai LifeSciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Massachusetts Financial Services Co. MA (3.25%), 12 West Capital Management LP (2.57%), Mackenzie Financial Corp (1.96%), Braidwell LP (1.58%), Clearbridge Investments LLC (1.23%) and Jennison Associates LLC (1.01%).

How do I buy shares of Maravai LifeSciences?

Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Maravai LifeSciences Stock Price, News & Analysis (NASDAQ:MRVI)

$5.37

+0.27 (+5.29%)

(As of 12/1/2023 ET)

Compare

Today's Range: $4.92
▼
$5.41
50-Day Range: $4.70
▼
$10.00
52-Week Range: $4.52
▼
$16.90

Volume: 2.74 million shs
Average Volume: 3.18 million shs
Market Capitalization: $1.35 billion

P/E Ratio: 29.83
Dividend Yield: N/A
Price Target: $13.90

Maravai LifeSciences MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 158.8% Upside
$13.90 Price Target
Short Interest: Healthy
6.68% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.23
Upright™ Environmental Score
News Sentiment: 1.26
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.10) to ($0.03) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.41 out of 5 stars

Medical Sector

275th out of 951 stocks

Biotechnology Industry

5th out of 30 stocks

3.3

Analyst's Opinion

Consensus Rating
Maravai LifeSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $13.90, Maravai LifeSciences has a forecasted upside of 158.8% from its current price of $5.37.
Amount of Analyst Coverage
Maravai LifeSciences has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
6.68% of the float of Maravai LifeSciences has been sold short.
Short Interest Ratio / Days to Cover
Maravai LifeSciences has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Maravai LifeSciences has recently decreased by 4.71%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Maravai LifeSciences does not currently pay a dividend.
Dividend Growth
Maravai LifeSciences does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Maravai LifeSciences has received a 67.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Deoxyribonucleic acid (DNA)", "Microbiology laboratory services for research", and "Clinical research services for genetic diseases" products. See details.
Environmental Sustainability
The Environmental Impact score for Maravai LifeSciences is -1.23.

2.4

News and Social Media Coverage

News Sentiment
Maravai LifeSciences has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Maravai LifeSciences this week, compared to 3 articles on an average week.
Search Interest
Only 2 people have searched for MRVI on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.
MarketBeat Follows
Only 68 people have added Maravai LifeSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -42% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Maravai LifeSciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.22% of the stock of Maravai LifeSciences is held by insiders.
Percentage Held by Institutions
50.25% of the stock of Maravai LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Maravai LifeSciences are expected to grow in the coming year, from ($0.10) to ($0.03) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Maravai LifeSciences is 29.83, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.76.
Price to Earnings Ratio vs. Sector
The P/E ratio of Maravai LifeSciences is 29.83, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 128.34.
Price to Book Value per Share Ratio
Maravai LifeSciences has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Maravai LifeSciences Stock (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, Viral Clearance Prediction kits, and custom services. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

MRVI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MRVI Stock News Headlines

November 24, 2023 | finance.yahoo.com

Are Options Traders Betting on a Big Move in Maravai LifeSciences (MRVI) Stock?

November 16, 2023 | finance.yahoo.com

Analyst Forecasts Just Became More Bearish On Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

December 2, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 9, 2023 | benzinga.com

Maravai LifeSciences Stock (NASDAQ:MRVI) Earnings Dates and Earning Calls

November 9, 2023 | finance.yahoo.com

Maravai LifeSciences Announces November 2023 Investor Conference Schedule

November 8, 2023 | msn.com

Maravai hits 52-week low after Q3 miss, cost cutting

November 8, 2023 | finance.yahoo.com

Maravai LifeSciences (MRVI) Q3 2023 Earnings Call Transcript

November 8, 2023 | seekingalpha.com

Maravai LifeSciences Holdings, Inc. 2023 Q3 - Results - Earnings Call Presentation

December 2, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

November 7, 2023 | benzinga.com

Maravai LifeSciences: Q3 Earnings Insights

November 7, 2023 | finance.yahoo.com

Maravai LifeSciences Holdings Inc (MRVI) Reports Q3 2023 Financial Results Amidst Market Realignment

November 2, 2023 | finance.yahoo.com

TriLink BioTechnologies® Expands Capabilities with Launch of ‘Analytical Sciences Center of Excellence’

October 28, 2023 | seekingalpha.com

Maravai LifeSciences: Falling Victim To COVID Boom And Bust

October 17, 2023 | finance.yahoo.com

Maravai LifeSciences To Host Earnings Conference Call on Tuesday, November 7, 2023

September 29, 2023 | finance.yahoo.com

Maravai LifeSciences Hosts 2023 Investor R&D Day

September 26, 2023 | finance.yahoo.com

Is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Expensive For A Reason? A Look At Its Intrinsic Value

September 5, 2023 | finance.yahoo.com

Maravai LifeSciences to Host 2023 Investor R&D Day

August 29, 2023 | markets.businessinsider.com

RBC Capital Sticks to Its Buy Rating for Maravai Lifesciences Holdings (MRVI)

August 23, 2023 | finance.yahoo.com

Cygnus Technologies Receives 2023 R&D 100 Award for MockV® RVLP Kit

August 22, 2023 | finance.yahoo.com

11 Most Undervalued Biotech Stocks to Buy According to Analysts

August 9, 2023 | finance.yahoo.com

Maravai LifeSciences Announces August 2023 Investor Conference Schedule

August 9, 2023 | finance.yahoo.com

What Does The Future Hold For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)? These Analysts Have Been Cutting Their Estimates

August 8, 2023 | 247wallst.com

KeyBanc Downgrades Maravai LifeSciences

August 8, 2023 | msn.com

Goldman Sachs Maintains Maravai LifeSciences Holdings Inc - (MRVI) Neutral Recommendation

August 8, 2023 | msn.com

Keybanc Downgrades Maravai LifeSciences Holdings Inc - (MRVI)

August 8, 2023 | msn.com

Maravai LifeSciences Holdings Non-GAAP EPS of $0.00 misses by $0.01, revenue of $68.9M misses by $2.23M

August 8, 2023 | seekingalpha.com

Maravai LifeSciences Holdings, Inc. 2023 Q2 - Results - Earnings Call Presentation

See More Headlines

Receive MRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2023
Today: 12/02/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/28/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MRVI
CUSIP: N/A
CIK: 1823239
Web: www.maravai.com
Phone: 858-546-0004
Fax: N/A
Employees: 660
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $13.90
High Stock Price Target: $24.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +158.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.18
Trailing P/E Ratio: 29.83
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $220.21 million
Net Margins: 5.86%
Pretax Margin: 13.69%
Return on Equity: 9.38%
Return on Assets: 3.70%

Debt

Debt-to-Equity Ratio: 0.62
Current Ratio: 8.96
Quick Ratio: 8.33

Sales & Book Value

Annual Sales: $883 million
Price / Sales: 1.53
Cash Flow: $2.07 per share
Price / Cash Flow: 2.60
Book Value: $3.55 per share
Price / Book: 1.51

Miscellaneous

Outstanding Shares: 251,280,000
Free Float: 250,730,000
Market Cap: $1.35 billion
Optionable: Not Optionable
Beta: -0.31

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Carl W. Hull (Age 64)
Co-Founder & Executive Chairman
Comp: $1.45M
Mr. William E. Martin III (Age 48)
Chief Executive Officer
Comp: $2.07M
Mr. Kevin M. Herde (Age 51)
Executive VP & CFO
Comp: $778.28k
Dr. Peter Michael Leddy Ph.D. (Age 60)
Executive VP & Chief Administrative Officer
Comp: $757k
Ms. Christine Dolan (Age 55)
Executive Vice President of Biologics Safety Testing
Comp: $755.97k
Ms. Debra Hart
Senior Director of Investor Relations
Mr. Kurt Oreshack (Age 42)
Executive VP, General Counsel & Secretary
Comp: $701.4k
Ms. Becky Buzzeo
Executive VP & Chief Commercial Officer
Dr. Kate E. Broderick Ph.D.
Chief Innovation Officer
Mr. Christopher Benoit
Executive Vice President of Enzymes

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

MRVI Stock Analysis - Frequently Asked Questions

Should I buy or sell Maravai LifeSciences stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Maravai LifeSciences in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MRVI shares.
View MRVI analyst ratings or view top-rated stocks.
What is Maravai LifeSciences' stock price target for 2024?: 8 Wall Street analysts have issued twelve-month price objectives for Maravai LifeSciences' stock. Their MRVI share price targets range from $7.00 to $24.00. On average, they predict the company's share price to reach $13.90 in the next twelve months. This suggests a possible upside of 158.8% from the stock's current price.
View analysts price targets for MRVI or view top-rated stocks among Wall Street analysts.
How have MRVI shares performed in 2023?: Maravai LifeSciences' stock was trading at $14.31 at the beginning of the year. Since then, MRVI shares have decreased by 62.5% and is now trading at $5.37.
View the best growth stocks for 2023 here.
When is Maravai LifeSciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our MRVI earnings forecast.
How were Maravai LifeSciences' earnings last quarter?: Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) issued its earnings results on Tuesday, November, 7th. The company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.03) by $0.01. The firm had revenue of $66.87 million for the quarter, compared to analyst estimates of $75.23 million. Maravai LifeSciences had a trailing twelve-month return on equity of 9.38% and a net margin of 5.86%.
What ETFs hold Maravai LifeSciences' stock?: ETFs with the largest weight of Maravai LifeSciences (NASDAQ:MRVI) stock in their portfolio include Morningstar US Small Growth (MSGR), Janus Henderson Small Cap Growth Alpha ETF (JSML), First Trust Health Care AlphaDEX Fund (FXH) and Putnam BioRevolution ETF (SYNB).WisdomTree U.S. SmallCap Fund (EES).

What guidance has Maravai LifeSciences issued on next quarter's earnings?: Maravai LifeSciences updated its FY23 earnings guidance on Tuesday, November, 7th. The company provided earnings per share (EPS) guidance of ($0.01) - $0.01 for the period, compared to the consensus EPS estimate of $0.06. The company issued revenue guidance of $275-285 million, compared to the consensus revenue estimate of $308.70 million.
When did Maravai LifeSciences IPO?: (MRVI) raised $1.3 billion in an IPO on Friday, November 20th 2020. The company issued 50,000,000 shares at a price of $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs acted as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers.
Who are Maravai LifeSciences' major shareholders?: Maravai LifeSciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Massachusetts Financial Services Co. MA (3.25%), 12 West Capital Management LP (2.57%), Mackenzie Financial Corp (1.96%), Braidwell LP (1.58%), Clearbridge Investments LLC (1.23%) and Jennison Associates LLC (1.01%).
How do I buy shares of Maravai LifeSciences?: Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:MRVI) was last updated on 12/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Maravai LifeSciences Stock Price, News & Analysis (NASDAQ:MRVI)

Maravai LifeSciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Maravai LifeSciences Stock (NASDAQ:MRVI)

MRVI Stock Price History

MRVI Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

MRVI Stock Analysis - Frequently Asked Questions

Overall MarketRank^™